Hyperfine, Inc. — Director's Dealing 2022

Feb 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hyperfine, Inc. (HYPR)
CIK: 0001833769
Period of Report: 2022-02-09

Reporting Person: Siddiqui Khan (Chief Medical Officer and CSO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-09	Stock Option (right to buy)	$3.90	A	110000	Acquired	2032-02-09	Class A Common Stock (110000)	Direct
2022-02-09	Stock Option (right to buy)	$3.90	A	74000	Acquired	2032-02-09	Class A Common Stock (74000)	Direct

Footnotes

F1: The shares underlying this option vest as to 25% on the date of grant, and 2.083% at the end of each month thereafter beginning on February 31, 2022, subject to Dr. Siddiqui's continued service through the applicable vesting date; provided that any vesting of the award will be delayed if as of the applicable vesting date a registration statement on Form S-8 registering shares under the registrant's 2021 Equity Incentive Plan has not yet been filed with the Securities and Exchange Commission, and in such event the number of options vesting on the first scheduled vesting date following the filing of the registration statement will also include any delayed vesting options.

F2: The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Dr. Siddiqui's continued service through the applicable vesting date.